MELISSA WALLACE: Open Payments
NPI 1023524501 · STATE COLLEGE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$414 in 22 payments from 8 companies in 2025. Trend: 2023 $1,162 · 2024 $943 · 2025 $414
Food & beverage: $414
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 8 | $152 |
| ABBVIE INC. | 5 | $86 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| PFIZER INC. | 2 | $35 |
| UROGEN PHARMA, INC. | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
Products named: GEMTESA, BOTOX, XTANDI, ORGOVYX, KEYTRUDA, ADSTILADRIN, ERLEADA.
Industry payments across PA — which companies pay providers there.
